DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH ADVANCED AND/OR METASTA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是找出激素抵抗、晚期或转移性前列腺癌患者外周血中是否存在肿瘤细胞。受试者被要求参与这项研究，因为他们被诊断出患有激素抵抗、晚期或转移性前列腺癌。血液样本将根据霍林斯癌症中心外科肿瘤学实验室由迈克·米塔斯博士(基础科学研究员)制定的方案进行分析。下列基因的表达：EpCAM1，EpCAM2，XAG，S100P，DAG1，Claudin7，Ese1，Mal2，Spint2，ERG和ETV1，将通过一种非常敏感的程序被称为“实时RT-PCR”来测量。大约10毫升的血样将被送往圣路易斯的华盛顿大学进行平行检测。这两个血液样本都没有识别符，只会被贴上一个随机的两位数字的标签。作为阴性对照，将使用健康志愿者的外周血液样本。这些样本已经由Mitas博士(基础科学研究人员)根据单独批准的方案获取。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out whether tumor cells are present in the peripheral blood of patients with hormone-resistant, advanced or metastatic prostate cancer. Subjects are being asked to participate in this study because they have been diagnosed with hormone-resistant, advanced or metastatic prostate cancer. Blood samples will be analyzed according to the protocol developed in the Surgical Oncology Laboratory of the Hollings Cancer center by Dr. Mike Mitas (basic science investigator). Expression of the following genes: EpCAM1, EpCAM2, XAG, S100P, DAG1, Claudin7, Ese1, Mal2, Spint2, ERG, and ETV1, will be measured by a very sensitive procedure known as "real-time RT-PCR". About 10 ml of the blood sample will be sent to Washington University in St. Louis to be tested in parallel. Both blood samples will have no identifiers and will be only labeled with a random two-digit number. As negative controls, peripheral blood samples from healthy volunteers will be used. These samples have already been acquired by Dr. Mitas (the basic science investigator) under a separate approved protocol.